OpenURL Connection Search

Select item for more details and to access through your institution.

AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: a prospective randomized study.
Published in:
2019
By:
- Koffi, K. G.;
- Silué, D. A.;
- Laurent, C.;
- Boidy, K.;
- Koui, S.;
- Compaci, G.;
- Adeba, Z. H.;
- Kamara, I.;
- Botty, R. P.;
- Bognini, A. S.;
- Sanogo, I.;
- Despas, F.;
- Laurent, G.
Publication type:
journal article
Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report.
Published in:
Journal of Clinical Pharmacy & Therapeutics, 2016, v. 41, n. 3, p. 360, doi. 10.1111/jcpt.12383
By:
- Tournaire, G.;
- Despas, F.;
- Huguet, F.;
- Montastruc, J. L.;
- Bondon‐Guitton, E.
Publication type:
Article
Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
Published in:
Journal of Clinical Pharmacy & Therapeutics, 2013, v. 38, n. 5, p. 341, doi. 10.1111/jcpt.12067
By:
- Pathak, A.;
- Lebrin, M.;
- Vaccaro, A.;
- Senard, J. M.;
- Despas, F.
Publication type:
Article
The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study.
Published in:
2016
By:
- Lamy, S.;
- Bettiol, C.;
- Grosclaude, P.;
- Compaci, G.;
- Albertus, G.;
- Récher, C.;
- Nogaro, J. C.;
- Despas, F.;
- Laurent, G.;
- Delpierre, C.
Publication type:
journal article
Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.
Published in:
Hematological Oncology, 2023, v. 41, p. 534, doi. 10.1002/hon.3164_397
By:
- Vic, S.;
- Thibert, J.;
- Bachy, E.;
- Cartron, G.;
- Gastinne, T.;
- Morschhauser, F.;
- Le Bras, F.;
- Bouabdallah, K.;
- Despas, F.;
- Bay, J.;
- Rubio, M.;
- Mohty, M.;
- Casasnovas, O.;
- Choquet, S.;
- Castilla‐Llorente, C.;
- Guidez, S.;
- Loschi, M.;
- Guffroy, B.;
- Carras, S.;
- La Rochelle, L. Drieu
Publication type:
Article
Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy.
Published in:
2016
By:
- Bondon-Guitton, E.;
- Combret, S.;
- Pérault-Pochat, M.;
- Stève-Dumont, M.;
- Bagheri, H.;
- Huguet, F.;
- Despas, F.;
- Pathak, A.;
- Montastruc, J.;
- Pérault-Pochat, M C;
- Stève-Dumont, M;
- Montastruc, J L
Publication type:
journal article

Found: 6

AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: a prospective randomized study.

Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report.

Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.

The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study.

Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.

Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy.